Pharsight

Dextenza patents expiration

DEXTENZA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9254267 OCULAR THERAPEUTIX Composite hydrogel drug delivery systems
Sep, 2024

(5 months from now)

US8563027 OCULAR THERAPEUTIX Drug delivery through hydrogel plugs
Feb, 2030

(5 years from now)

US8409606 OCULAR THERAPEUTIX Drug delivery through hydrogel plugs
May, 2030

(6 years from now)

US11458041 OCULAR THERAPEUTIX Punctal plug and bioadhesives
Nov, 2037

(13 years from now)

Dextenza is owned by Ocular Therapeutix.

Dextenza contains Dexamethasone.

Dextenza has a total of 4 drug patents out of which 0 drug patents have expired.

Dextenza was authorised for market use on 30 November, 2018.

Dextenza is available in insert;ophthalmic dosage forms.

Dextenza can be used as treatment of ocular itching associated with allergic conjunctivitis; treatment of ocular inflammation and pain following ophthalmic surgery, dextenza is approved for the treatment of ocular pain following ophthalmic surgery.

The generics of Dextenza are possible to be released after 16 November, 2037.

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Oct 7, 2024

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 30 November, 2018

Treatment: Dextenza is approved for the treatment of ocular pain following ophthalmic surgery; Treatment of ocular itching associated with allergic conjunctivitis; Treatment of ocular inflammation and pain follo...

Dosage: INSERT;OPHTHALMIC

More Information on Dosage

DEXTENZA family patents

Family Patents